Change in Antiplatelet Therapy in Prevention of Secondary Stroke (CAPS2) study

Sen, Souvik; Redd, Kolby T; Lim, Mihyun; Kothari, Ravish; Duda, Julian; Giamberardino, Lauren

doi:10.4172/2329-6895.1000385

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to demographics, data were collected on the following stroke risk factors: hypertension (previously diagnosed and treatment with an antihypertensive medication), diabetes (previously diagnosed with or without treatment with a medication for glycemic control), hyperlipidemia (previously diagnosed with or without treatment with cholesterol-lowering medications), cigarette smoker (smoking one or more cigarettes daily) [13]. Stroke etiology was classified using the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria [14].…”

Section: Baseline Characteristics and Ischemic Stroke Subtype Assessmentmentioning

confidence: 99%

Development and initial validation of a patient‐centered stroke outcome measure in young stroke survivors

Kodumuri

Edmunds

Seidel

et al. 2021

Euro J of Neurology

Self Cite

View full text Add to dashboard Cite

Background and purpose This study was undertaken to develop a patient‐centered stroke outcome measure and initial validation of the proposed Young Stroke Questionnaire (YSQ). Methods This study assessed the reliability and discriminant validity of the YSQ. The initial questionnaire evolved from a focus group comprised of six young stroke survivors and six stroke neurologists centralized around four patient‐centered domains. To determine the reliability and discriminant validity of the YSQ, 100 young stroke survivors were recruited and provided consent. Standardized clinical assessments completed included the modified Rankin Scale (mRS), National Institutes of Health Stroke Scale, and Stroke Impact Scale. Additionally, all patients were asked to complete the patient‐centered YSQ. Results Of the 100 enrolled patients in the study (mean age ± standard deviation = 49 ± 11.3, 58% females, 53% African American, 44% White), Cronbach alpha for all domains was >0.7. Moreover, Cronbach alpha for entire questionnaire was >0.9, indicating that the scale, with four subdomains, is internally consistent and reproducible. Discriminant validity of the scale was assessed by comparing the means of each subdomain of the YSQ among healthy subjects to the groups of stroke patients as defined by the mRS. The YSQ was able to differentiate subjects with good outcome (mRS = 0–1) from subjects with varying degree of disability as defined by the mRS (p = 0.026). Conclusions Standardized clinical assessments are not sensitive to disabilities in young stroke survivors. When compared to standardized clinical assessments, the YSQ is significantly capable of differentiating the young survivor perspective of the impact of stroke in all four subdomains.

show abstract

Section: Baseline Characteristics and Ischemic Stroke Subtype Assessmentmentioning

confidence: 99%